Current Edition

clinical

CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD

Patient enrollment proceeding under amended protocol CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV) infection and immunologic …

Continue Reading →